Wiener klinische Wochenschrift

, Volume 124, Supplement 2, pp 42–49 | Cite as

Diabetische Nephropathie – Update 2012

Positionspapier der Österreichischen Diabetes Gesellschaft und der Österreichischen Gesellschaft für Nephrologie unter Mitarbeit von
  • Martin Auinger
  • Roland Edlinger
  • Friedrich Prischl
  • Alexandra Kautzky-Willer
  • Rudolf Prager
  • Alexander R. Rosenkranz
  • Michael Roden
  • Marcus Saemann
  • Martin Clodi
  • Guntram Schernthaner
leitlinien für die praxis

Zusammenfassung

Diabetische Nephropathie ist die führende Ursache der Nierenersatztherapie und die häufigste Nierenkrankheit geworden. Die Entwicklung und das Fortschreiten kann durch optimierte Therapie beeinflusst werden. Im vorliegenden Artikel werden die gemeinsamen Empfehlungen der Österreichischen Diabetesgesellschaft und der Österreichischen Gesellschaft für Nephrologie dargestellt.

Diabetic nephropathy—update 2012

Summary

Diabetes mellitus is the leading single cause for renal replacement therapy. Its development and progression, however, can be ameliorated by adequate therapy. The present article represents the recommendations of the Austrian Diabetes Association and the Austrian Society for Nephrology for the prevention and treatment of diabetic nephropathy.

Literatur

  1. 1.
    KDOQI. KDOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39(Suppl 1):1–266.Google Scholar
  2. 2.
    Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16(1):31–41.PubMedCrossRefGoogle Scholar
  3. 3.
    Levey AS, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Ann Intern Med. 1999;130(6):461–70.PubMedGoogle Scholar
  4. 4.
    Levey A, Coresh J, Greene T, Marsh J, Stevens LA, Kusek J, Van Lente F. Expressing the MDRD study equation for estimating GFR with IDMS traceable (gold standard) serum creatinine values. J Am Soc Nephrol. 2005;16(Abstractissue):October 2005: 69A.Google Scholar
  5. 5.
    Levey AS et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604–12.PubMedGoogle Scholar
  6. 6.
    Kalantar-Zadeh K, Amin AN. Toward more accurate detection and risk stratification of chronic kidney disease. JAMA. 2012;307(18):1976–7.PubMedCrossRefGoogle Scholar
  7. 7.
    Kramer HJ, et al. Renal insufficiency in the absence of albuminuria and retinopathy among adults with type 2 diabetes mellitus. JAMA. 2003;289(24):3273–7.PubMedCrossRefGoogle Scholar
  8. 8.
    Retnakaran R, et al. Risk factors for renal dysfunction in type 2 diabetes: u.k. prospective diabetes study 74. Diabetes. 2006;55(6):1832–9.Google Scholar
  9. 9.
    Thomas MC, et al. Nonalbuminuric renal impairment in type 2 diabetic patients and in the general population (National Evaluation of the Frequency of Renal Impairment cO-existing with NIDDM [NEFRON] 11). Diabetes Care. 2009;32(8):1497–502.PubMedCrossRefGoogle Scholar
  10. 10.
    DDG NV, Nierenerkrankungen bei Diabetes im Erwachsenenalter. DDG. 2011. www.deutsche-diabetes-gesellschaft.de.
  11. 11.
    KDOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am. J. Kidney Dis. 2004;43:1–290.Google Scholar
  12. 12.
    The ACCORD Study Group. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med. 2010;362(17):1575–85.CrossRefGoogle Scholar
  13. 13.
    Bangalore S, et al. Blood pressure targets in subjects with type 2 diabetes mellitus/impaired fasting glucose: observations from traditional and bayesian random-effects meta-analyses of randomized trials. Circulation. 2011;123(24):2799–810.PubMedCrossRefGoogle Scholar
  14. 14.
    Members ATF, et al. European guidelines on cardiovascular disease prevention in clinical practice (version 2012). Eur. Heart J. 2012;33(13):1635–701.CrossRefGoogle Scholar
  15. 15.
    Hochdruckliga EVD, Leitlinien für die Prävention, Erkennung, Diagnostik und Therapie der arteriellen Hypertonie – neue Entwicklungen in der Hochdrucktherapie; update. 2011. www.hochdruckliga.de.Google Scholar
  16. 16.
    Nilsson PM, What Blood Pressure Goal in Type-2 Diabetes? J Hypertonie. 2011;15(4):9–14.Google Scholar
  17. 17.
    Ruggenenti P, et al. Preventing microalbuminuria in type 2 diabetes. N Engl J Med. 2004;351(19):1941–51.PubMedCrossRefGoogle Scholar
  18. 18.
    Haller H, et al. Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. N Engl J Med. 2011;364(10):907–17.PubMedCrossRefGoogle Scholar
  19. 19.
    Lewis JB, et al. Effect of intensive blood pressure control on the course of type 1 diabetic nephropathy. collaborative study group. Am. J. Kidney Dis. 1999;34(5):809–17.PubMedCrossRefGoogle Scholar
  20. 20.
    ADA. Standards of medical care in diabetes – 2012. Diabetes Care. 2012;35(Supplement 1):11–63.Google Scholar
  21. 21.
    Bakris GL, et al. Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial. Lancet. 2010;375(9721):1173–81.PubMedCrossRefGoogle Scholar
  22. 22.
    Mann JFE, et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet. 2008;372(9638):547–53.PubMedCrossRefGoogle Scholar
  23. 23.
    Redon J, et al. Safety and efficacy of low blood pressures among patients with diabetes: subgroup analyses from the ONTARGET (ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial). J Am Coll Cardiol. 2012;59(1):74–83.PubMedCrossRefGoogle Scholar
  24. 24.
    Watschinger B. Stellungnahme des Vorstands der ÖGH zur Doppelblockade des RAS. J Hypertonie. 2012;16(1):28.Google Scholar
  25. 25.
    Joannidis M, Schmid M, Wiedermann CJ. Prevention of contrast media-induced nephropathy by isotonic sodium bicarbonate: a meta-analysis. Wien Klin Wochenschr. 2008;120(23–24):742–8.PubMedCrossRefGoogle Scholar
  26. 26.
    Kiski D, et al. Impact of renin-angiotensin-aldosterone blockade by angiotensin-converting enzyme inhibitors or AT-1 blockers on frequency of contrast medium-induced nephropathy: a post-hoc analysis from the Dialysis-versus-Diuresis (DVD) trial. Nephrol Dial Transplant. 2010;25(3):759–64.PubMedCrossRefGoogle Scholar
  27. 27.
    KDOQI. Clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease. Am J Kidney Dis. 2007;49(2):12–154.CrossRefGoogle Scholar
  28. 28.
    The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329(14):977–86.CrossRefGoogle Scholar
  29. 29.
    UKPDS. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352(9131):837–53.CrossRefGoogle Scholar
  30. 30.
    Lewis EJ, et al. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The collaborative study group. N Engl J Med. 1993;329(20):1456–62.PubMedCrossRefGoogle Scholar
  31. 31.
    Brenner BM, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345(12):861–9.PubMedCrossRefGoogle Scholar
  32. 32.
    Parving HH, et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med. 2001;345(12):870–8.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Wien 2012

Authors and Affiliations

  • Martin Auinger
    • 1
  • Roland Edlinger
    • 1
  • Friedrich Prischl
    • 2
  • Alexandra Kautzky-Willer
    • 3
  • Rudolf Prager
    • 1
  • Alexander R. Rosenkranz
    • 4
  • Michael Roden
    • 5
  • Marcus Saemann
    • 6
  • Martin Clodi
    • 3
  • Guntram Schernthaner
    • 7
  1. 1.3. Medizinische AbteilungKrankenhaus Hietzing der Stadt Wien, und Karl Landsteiner Institut für Stoffwechselerkrankungen und NephrologieWienÖsterreich
  2. 2.IV. Interne Abteilung/Bereich NephrologieKlinikum Wels-GrieskirchenWelsÖsterreich
  3. 3.Klinische Abteilung für Endokrinologie und Stoffwechsel, Universitätsklinik für Innere Medizin IIIMedizinische Universität WienWienÖsterreich
  4. 4.Klinische Abteilung für NephrologieUniversitätsklinik für Innere Medizin GrazGrazÖsterreich
  5. 5.Deutsches Diabeteszentrum und Klinik für StoffwechselerkrankungenHeinrich Heine UniversitätDüsseldorfDeutschland
  6. 6.Klinische Abteilung für NephrologieUniv. Klinik für Innere Medizin III, Medizinische Universität WienWienÖsterreich
  7. 7.1.Medizinische AbteilungKrankenhaus RudolfstiftungWienÖsterreich

Personalised recommendations